AU2001289896A1 - Mechanically stable dosage forms containing ubiquinones - Google Patents

Mechanically stable dosage forms containing ubiquinones

Info

Publication number
AU2001289896A1
AU2001289896A1 AU2001289896A AU8989601A AU2001289896A1 AU 2001289896 A1 AU2001289896 A1 AU 2001289896A1 AU 2001289896 A AU2001289896 A AU 2001289896A AU 8989601 A AU8989601 A AU 8989601A AU 2001289896 A1 AU2001289896 A1 AU 2001289896A1
Authority
AU
Australia
Prior art keywords
dosage forms
mechanically stable
forms containing
stable dosage
ubiquinones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289896A
Inventor
Jorg Breitenbach
Jorg Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of AU2001289896A1 publication Critical patent/AU2001289896A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001289896A 2000-09-19 2001-09-19 Mechanically stable dosage forms containing ubiquinones Abandoned AU2001289896A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10046541 2000-09-19
DE10046541.2 2000-09-19
DE10046541A DE10046541A1 (en) 2000-09-19 2000-09-19 Oral dosage form useful as nutritional supplement or medicament comprises solid dispersion of ubiquinone in thermoplastic matrix
PCT/EP2001/010830 WO2002024184A2 (en) 2000-09-19 2001-09-19 Mechanically stable dosage forms containing ubiquinones

Publications (1)

Publication Number Publication Date
AU2001289896A1 true AU2001289896A1 (en) 2002-04-02

Family

ID=7656929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289896A Abandoned AU2001289896A1 (en) 2000-09-19 2001-09-19 Mechanically stable dosage forms containing ubiquinones

Country Status (6)

Country Link
US (1) US7273624B2 (en)
EP (1) EP1318799B1 (en)
AU (1) AU2001289896A1 (en)
DE (2) DE10046541A1 (en)
ES (1) ES2315304T3 (en)
WO (1) WO2002024184A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
CA2359945C (en) * 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (en) * 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
CA2578356C (en) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
US7884131B2 (en) * 2004-11-19 2011-02-08 Martek Biosciences, Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20060224095A1 (en) * 2005-04-05 2006-10-05 University Of New Hampshire Biocompatible polymeric vesicles self assembled from triblock copolymers
US20060257385A1 (en) * 2005-04-14 2006-11-16 Rogovin Jarrow L Dietary supplement formulations for improved delivery of coenzyme Q10 and methods of administration
WO2007014392A2 (en) * 2005-07-28 2007-02-01 Isp Investments Inc. Benzoquinones of enhanced bioavailability
EP1912626B1 (en) 2005-08-08 2016-04-13 AbbVie Deutschland GmbH & Co KG Dosage forms with improved bioavailability
US8486456B2 (en) 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability
KR100754953B1 (en) 2005-09-14 2007-09-04 주식회사 대웅 A solublized material comprising ubidecarenone, aqueous solution and process for preparation thereof
CN102872157A (en) * 2005-12-07 2013-01-16 奈科明制药有限公司 Pre-compacted calcium-containing compositions
WO2007090162A2 (en) * 2006-01-31 2007-08-09 Martek Biosciences Corporation OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
CN101663031A (en) * 2007-02-20 2010-03-03 马泰克生物科学公司 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
SI2180882T1 (en) * 2007-10-19 2013-05-31 Otsuka Pharmaceutical Co., Ltd. Solid matrix pharmaceutical preparation
WO2009086281A1 (en) * 2007-12-21 2009-07-09 Martek Biosciences Corporation Method for preparation of oxylipins
WO2009117152A1 (en) 2008-03-20 2009-09-24 Virun, Inc. Emulsions including a peg-derivative of tocopherol
US8765661B2 (en) 2008-03-20 2014-07-01 Virun, Inc. Compositions containing non-polar compounds
AR071375A1 (en) 2008-04-22 2010-06-16 Solvay Pharm Gmbh FORMULATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF DEFICIENT PERMEABILITY, PREPARATION AND PRODUCT PROCESS
US8337931B2 (en) * 2008-06-23 2012-12-25 Virun, Inc. Compositions containing non-polar compounds
CN102413813B (en) * 2009-03-24 2014-11-12 Adds制药有限责任公司 Stabilized solubility-enhanced formulations for oral delivery
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
CN103037708B (en) * 2010-03-23 2015-05-20 维尔恩公司 Nanoemulsion including sucrose fatty acid ester
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US8834942B2 (en) 2010-12-01 2014-09-16 PruGen IP Holdings, Inc. Enhanced absorption of oregano derived oils
PE20181177A1 (en) 2010-12-22 2018-07-20 Purdue Pharma Lp ENCLOSED CONTROLLED RELEASE DOSE FORMS RESISTANT TO IMPROPER HANDLING
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
SG11201404640YA (en) 2012-02-10 2014-09-26 Virun Inc Beverage compositions containing non-polar compounds
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
SI2950786T1 (en) 2013-01-31 2020-03-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
ES2900570T3 (en) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
CN111388434A (en) * 2020-04-09 2020-07-10 天津仁卫生物医药科技有限公司 Orally disintegrating tablet for improving stability of main drug by using solid dispersion and preparation method thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52136912A (en) * 1976-05-06 1977-11-16 Eisai Co Ltd Solia agent
IT1191608B (en) * 1985-02-01 1988-03-23 Zambon Spa PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL FORMS THAT CONTAIN IT
DE3612212A1 (en) * 1986-04-11 1987-10-15 Basf Ag METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS
DE3612211A1 (en) * 1986-04-11 1987-10-15 Basf Ag CONTINUOUS TABLET METHOD
JPH06218028A (en) * 1992-10-02 1994-08-09 Eisai Co Ltd Method and apparatus for molding wet-processed tablet, and the wet-processed tablet
IT1256386B (en) * 1992-11-13 1995-12-04 Luigi Boltri PHARMACEUTICAL COMPOSITIONS INCLUDING A DRUG, A CROSS-LINKED POLYMERIC SUBSTANCE, AN OIL AND A SURFACTIVE AGENT
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
DE4327063A1 (en) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenone particles with modified physicochemical properties
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
JP3889481B2 (en) * 1996-08-16 2007-03-07 株式会社カネカ Pharmaceutical composition
WO1998008490A1 (en) 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
IL134701A0 (en) 2000-02-23 2001-04-30 J P M E D Ltd Homogeneous solid matrix containing vegetable proteins
US6806069B2 (en) * 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
JP3549197B2 (en) * 2001-08-10 2004-08-04 日清ファルマ株式会社 Ubiquinone-containing preparations
ITRM20030153A1 (en) * 2003-04-03 2004-10-04 Exall S R L WATER SOLUBLE FORMULATION CONTAINING UBICHINONE FOR OPHTHALMIC USE.

Also Published As

Publication number Publication date
WO2002024184A2 (en) 2002-03-28
DE50114549D1 (en) 2009-01-15
US20040014817A1 (en) 2004-01-22
EP1318799A2 (en) 2003-06-18
EP1318799B1 (en) 2008-12-03
ES2315304T3 (en) 2009-04-01
DE10046541A1 (en) 2002-03-28
US7273624B2 (en) 2007-09-25
WO2002024184A3 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
AU2001289896A1 (en) Mechanically stable dosage forms containing ubiquinones
AU2001233738A1 (en) Improved paste formulations
AU2002218250A1 (en) Medicament dispenser
AU2001295657A1 (en) Formulation containing wax-esters
AU2001260327A1 (en) Chair
AU2002223028A1 (en) Inhaler
AU2001292185A1 (en) Formulation containing amoxicillin
AU2002217464A1 (en) Medicinal compositions containing aspirin
AU2001234114A1 (en) Drugs containing combined active ingredients
AU2001263839A1 (en) Liquid formulations
AU2002223562A1 (en) Medicament dispenser
AU2001267707A1 (en) Antiperspirant formulations
AU2001282607A1 (en) Solution preparations stabilized over long time
AU2002214324A1 (en) Medicinal compositions
AU2001290239A1 (en) Medicinal composition
AU2001248833A1 (en) Stable liquid preparation
AUPQ761100A0 (en) Lipophilic medicament
AP2003002783A0 (en) Medicament containing activted antihtrombin iii
AU2001260270A1 (en) Liposomes containing active substances
AU2001267693A1 (en) Antiperspirant formulations
AU2001232244A1 (en) Drug comprising combination
AUPQ634300A0 (en) Synergistic formulations
AU2001286996A1 (en) Stabilized fgf formulations containing reducing agents
AU2002241767A1 (en) Concurrent-multitasking processor
AU9517501A (en) Composition containing leishmania LIP2A